





LESSONS FROM INDIA'S COVID-19 RESPONSE PRIVATE SECTOR AND INNOVATIONS

Dinesh Nair

Senior Health Specialist Health Nutrition and Population Global Practice World Bank







PRIVATE SECTOR PARTICIPATION

- Private sector- 65-75% of the healthcare in India
- Complete & updated data on private sector facilities, beds, ICUs, ventilators not available at national & state level
- High cost of care: Rate caps released, but partial success
- Limited participation and collaboration with public sector
 - Small private hospitals were closed particularly during the first waves.
 - Pooling & triaging between public and private hospitals attempted in several states with limited success
- States faced challenge in negotiating with the private sector and also the mechanisms, needed enforcement under Epidemic Act.

Pre-COVID status (NHP 2019)

	Public	Private
Hospitals	25778	43487
Beds	713986	118524 2
ICU beds	35699	59262
Ventilators	17850	29631

COVID diagnostic service: Half of the labs were from private sector (1700/ 3400) Not uniform across states.

Odisha: State collaborated with private hospitals in Public-Private Partnerships (PPP) mode (rental basis with tripartite MOUs) to set-up 17 dedicated COVID hospitals across the state, in addition to the 30 district hospitals. The payments to these private hospitals were made irrespective of the bed occupancy.

"Private sector participation was clearly missing in the first wave". Central Level Officer







COVID LABORATORY NETWORK AND TESTING

- Expanded laboratories network; one lab (Jan 2020) to ~3400 labs (Dec 2022), all ICMR portal linked; most NABL accredited
- Every district has RTPCR lab
- Leveraged TruNAAT facilities (TB program)
- Large share of private labs (1700+)
- ICMR ensured supply of the kits and supplies, quality assurance measures
- Mission 'Lifeline UDAAN' (MoCA & IAF) support during the lockdown phases
- Central procurement agency for equipment and kits

Meghalaya: Installed TruNAAT at District hospitals. In some districts, mobile laboratories were used.

Tamil Nadu- Relied only on RTPCR test and didn't use RAT test.



COVID Laboratory Network in India (2020-2022): Combined Public and Private Sector







INNOVATE IN INDIA FOR INCLUSIVENESS (i3) - P156241

The objective of the Project is to facilitate innovation in biopharmaceutical products and medical devices that address public health priorities in India.

- **Component 1:** Strengthening the pilot-to-market innovation ecosystem- Shared facilities, Clinical trial networks ; Scientific Research and Training
- **Component 2:** Accelerating the pilot-to-market process for specific products- Vaccines, Biosimilars, Equipment

- **COVID 19 Vaccines :** development of six novel COVID vaccine candidates (e.g., DNA, Adenovirus, Virosome, Subunit)
- **COVID Tests and Medical Devices :** developed RT-PCR Diagnostic Kits for detection of COVID-19 infection, Ventilators, Nucleic Extraction Kits, Material and Viral Transfer Medium, and Pulse Oximeters.
- **COVID-19 Therapeutics:** Virafin and Novel therapeutic antibodies
- Clinical Trial Networks : 5 field sites for vaccine clinical trials



